The Moment Of Truth For Three Alzheimer’s Drugs Beckons: What To Expect
Eisai/Biogen And Roche Phase III Readouts Expected Soon
After the Aduhelm controversy, Eisai/Biogen, Roche and Lilly are lining up Phase III results for their candidates which, against the odds, they hope could finally represent real progress in Alzheimer’s treatment. Scrip takes a look at the key questions surrounding the field as the drugs await their fate.
You may also be interested in...
ICER Sets Ceiling For Anti-Amyloid Pricing; Will Eisai And Lilly Raise The Roof?
The independent drug pricing watchdog said lecanemab and donanemab would be cost-effective at $8,500-$20,600 per year, but pricing has been expected to be closer to Aduhelm’s $28,200 price tag.
CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure
Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody.
Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen’s Lecanemab Readout
Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.